Biomarkers

\r\n Biomarker is a measurable indicator of the severity or presence of some disease state.
\r\n Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, and use estimated at $8.3 billion in 2007 and projected to increase to $15 billion in 2019. The accelerating pace of activity in this area is further underlined by a cursory review of the publication space, where the number of relevant scientific articles generated annually has doubled from 20,000 to 40,000 over the past decade. AACR, in partnership with the Food and Drug Administration (FDA) and National Cancer Institute (NCI), formed the AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC) to accelerate the translation of cancer therapeutics into the clinic by shaping the processes for the effective development of validated biomarkers and their use in clinical trials for maximum patient benefit.

\r\n

Biomarkers are any measurable characteristics that reflect a particular physiological state of an organism. They are also important in the development of new drug therapies through the discovery of "druggable targets." They have the potential to speed development of new disease therapies through the use of progression markers to delineate the development and course of a disease.

    Related Conference of Biomarkers

    Biomarkers Conference Speakers